search indicatorNeed Help?

Books by Subject

PharmacologyAccess restricted to Stanford unless otherwise noted

  • New strategies for traditional medicine -- Developing better herbal medicines in the post-genomic era -- Revitalization of the knowledge of herbs: a way forward to discovery of new drugs -- Ethnobotanical uses of the native flora from Brazilian north-eastern region -- Diversity and uses of the genus croton (euphorbiaceae) in Northeastern Brazil -- Ethnomedical knowledge among the "Quilombolas" from the Amazon region of Brazil with a special focus on plants used as nervous system tonics -- Advances in the knowledge of medicinal plants in Eastern Andalusia, Spain -- Tropical propolis: recent advances in chemical components and Botanical origin -- Anti-malarial plants used in folk medicine in Bangladesh -- Usnea sulcata motyka: an ethnomycological review of its use in traditional medicine -- Sirukurinjan: An ancient remedy for a modern incurable disease, diabetes -- Herbal drugs used for domestic animals -- Endophytes from medicinal plants as novel sources of bioactive compounds -- Advances in medicinal plants with antitumoral activity -- Medicinal plants: how are they used to treat neurological diseases? -- Inflammatory diseases: mechanisms and natural remedies -- Recent advances to evaluate anti-diabetic medicinal plants -- Botanical origin and Biological activity of propolis -- Bioactivity of plant essential oils -- Antibacterial and antiviral effects of aromatic plant-derived essential oils: a scientific and medicinal approach -- Strategies of solvent system selection for the isolation of natural products by countercurrent chromatography.
  • Metabolic syndrome is a common syndrome affecting about 20% of the adult population in Europe, and the prevalence is likely similar in other industrialised countries worldwide. It is mainly caused by the western lifestyle, which tends to produce abdominal obesity, but a genetic predisposition also plays a part. This syndrome, which is linked to leisure lifestyles and overeating/obesity, can develop into type 2 diabetes, cardiovascular disease and cancer. Therefore, proper treatment and prevention are essential. This book discusses lifestyle intervention and treatment, specifically with pharmacological compounds, in order to formulate a strategy for treating the metabolic syndrome in daily practice.
  • Chapter 1. ₃Li Lithium Metallotherapeutics / Robin S.B. Williams and Adrian J. Harwood, p. 1-17 -- Chapter 2. ₅B Boron Compounds as Therapeutic Drugs / Geeta Rana, Kamesh Vyakaranam, John A. Maguire and Narayan S. Hosmane, p. 19-49 -- Chapter 3. ₁₂Mg The Role of Magnesium As a Metallotherapeutic Drug / Pietro Delva, p. 51-64 -- Chapter 4. ₁₃Al Aluminum Metallotherapeutics / Thanos Salifoglou, p. 65-82 -- Chapter 5. ₁₄Si Biological Activity of Organosilicon Compounds / Edmunds Lukevics and Luba Ignatovich, p. 83-107 -- Chapter 6. ₂₀Ca The Role of Calcium As a Metallotherapeutic Drug / Mario Barbagallo and Ligia J. Dominguez, p. 109-124 -- Chapter 7. ₂₂Ti Anti-Tumor Titanium Drugs / Erich Dubler, p. 125-142 -- Chapter 8. ₂₃V Insulin-Mimetic Vanadium-Containing Compounds / Tamás Kiss and Tamás Jakusch, p. 143-158 -- Chapter 9. ₂₅Mn Manganese Metallotherapeutics / Jeanne H. Freeland-Graves, Tanushree Bose and Abbass Karbassian, p. 159-178 -- Chapter 10. ₂₆Fe The Use of Iron-Based Drugs in Medicine / Xiang Wu and Mei Lin Go, p. 179-200 -- Chapter 11. ₂₇Co Cobalt Complexes As Potential Pharmaceutical Agents / Hui Chao and Liang-Nian Ji, p. 201-218 -- Chapter 12. ₂₉Cu Chemotherapeutic Copper Compounds / Francisco González-Vílchez and Rosario Vilaplana, p. 219-236 -- Chapter 13. ₃₀Zn The Role of Zinc As a Metallotherapeutic Agent / Jane V. Higdon and Emily Ho, p. 237-257 -- Chapter 14. ₃₁Ga Therapeutic Gallium Compounds / Lawrence R. Bernstein, p. 259-277 -- Chapter 15. ₃₂Ge Biological Activity of Organogermanium Compounds / Edmunds Lukevics and Luba Ignatovich, p. 279-295 -- Chapter 16. ₃₃As Metallotherapeutic Arsenic Compounds / Paul C. Ho, p. 297-311 -- Chapter 17. ₃₄Se The Use of Selenium-Based Drugs in Medicine / Michael Carland and Tahli Fenner, p. 313-332 -- Chapter 18. ₄₃Tc Technetium in Medicine / Oyebola O. Sogbein and John F. Valliant, p. 333-358 -- Chapter 19. ₄₄Ru Perspectives of Ruthenium Complexes in Cancer Therapy / Olivier Lentzen, Cécile Moucheron and Andrée Kirsch-De Mesmaeker, p. 359-378 -- Chapter 20. ₄₅Rh Rhodium in Medicine / Florian P. Pruchnik, p. 379-397 -- Chapter 21. ₄₆Pd The Use of Palladium Complexes in Medicine / Achilleas Garoufis, Sotiris K. Hadjikakou and Nick Hadjiliadis, p. 399-419 -- Chapter 22. ₅₀Sn Tin Compounds and Their Therapeutic Potential / Marcel Gielen and Edward R.T. Tiekink, p. 421-439 -- Chapter 23. ₅₁Sb Antimony in Medicine / Siucheong Yan, Lan Jin and Hongzhe Sun, p. 441-461 -- Chapter 24. ₇₅Re Therapeutic Rhenium Radiopharmaceuticals / Jonathan R. Dilworth and Paul S. Donnelly, p. 463-487 -- Chapter 25. ₇₈Pt Platinum-Based Drugs / Viktor Brabec and Jana Kasparkova, p. 489-506 -- Chapter 26. ₇₉Au Gold-Based Metallotherapeutics: Use and Potential / Soo Yei Ho and Edward R.T. Tiekink, p. 507-527 -- Chapter 27. ₈₃Bi Bismuth-Based Pharmaceuticals / Neil Burford and Melanie D. Eelman, p. 529-540 -- Chapter 28. Paramagnetic Metal Complexes As Contrast Agents for Magnetic Resonance Imaging / Silvio Aime, Alessandro Barge, Eliana Gianolio, Simonetta Geninatti Crich, Walter Dastrú and Fulvio Uggeri, p. 541-560.
  • Methylxanthines 2011, Springer
    Notes on the History of Caffeine Use / Bertil B. Fredholm -- Distribution, Biosynthesis and Catabolism of Methylxanthines in Plants / Hiroshi Ashihara, Misako Kato and Alan Crozier -- Pharmacokinetics and Metabolism of Natural Methylxanthines in Animal and Man / Maurice J. Arnaud -- Inhibition of Cyclic Nucleotide Phosphodiesterases by Methylxanthines and Related Compounds / Sharron H. Francis, Konjeti R. Sekhar, Hengming Ke and Jackie D. Corbin -- Methylxanthines and Ryanodine Receptor Channels / Serge Guerreiro, Marc Marien and Patrick P. Michel -- Xanthines as Adenosine Receptor Antagonists / Christa E. Müller and Kenneth A. Jacobson -- Theobromine and the Pharmacology of Cocoa / Hendrik Jan Smit -- Propentofylline: Glial Modulation, Neuroprotection, and Alleviation of Chronic Pain / Sarah Sweitzer and Joyce De Leo -- Methylxanthines, Seizures, and Excitotoxicity / Detlev Boison --Impacts of Methylxanthines and Adenosine Receptors on Neurodegeneration: Human and Experimental Studies / Jiang-Fan Chen and Yijuang Chern -- Methylxanthines and Pain / Jana Sawynok -- Methylxanthines and Sleep / Tarja Porkka-Heiskanen -- Methylxanthines and Reproduction / Alba Minelli and Ilaria Bellezza -- Methylxanthines During Pregnancy and Early Postnatal Life / Ulrika Ådén -- Methylxanthines and the Kidney / Hartmut Osswald and Jürgen Schnermann -- The Cardiovascular Effects of Methylxanthines / Niels P. Riksen, Paul Smits and Gerard A. Rongen -- Methylxanthines in Asthma / Stephen L. Tilley -- Methylxanthines and Inflammatory Cells / György Haskó and Bruce Cronstein -- Methylxanthines, Inflammation, and Cancer: Fundamental Mechanisms / Akio Ohta and Michail Sitkovsky -- Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse / Micaela Morelli and Nicola Simola -- Methylxanthines and Human Health: Epidemiological and Experimental Evidence / Marie-Soleil Beaudoin and Terry E. Graham.
  • In vivo target site concentrations are probably the most important determinant of drug effects. Traditionally, linking drug concentrations to drug effects has been accomplished by modelling blood-derived data, mostly because a direct quantification of tissue concentrations has been beyond technical reach. Today, a direct measurement of target site concentrations is possible by employing microdialysis or complementary approaches such as imaging technologies. Microdialysis, initially conceived in the 1970s, has become a standard tool in drug development. This comprehensive overview of current microdialysis technology covers general and disease-specific aspects of microdialysis by international experts in the field. It provides useful information for colleagues in academia and industry who are interested PK-PD aspects of drug development.
  • Modern anesthetics 2008, Springer
  • "Preface Over the past few decades, molecular modeling (MM) has become an important tool in many academic institutions and industrial laboratories. While the role of MM in biological fields--especially in the design and development of novel drug molecules or formulations--is well established and acknowledged, its direct role in the design and development of performance chemicals and novel materials is still not well known. Questions such as, which new products have resulted from an MM-based approach? are still often asked. Although MM may be playing an important role in product development, quite often it becomes difficult to predict its direct impact because most of the time the problem being addressed involves a multidisciplinary approach. Further, the assumption that fundamental phenomena being modeled though MM will have a direct impact on the macroscopic and functional properties of a product make the situation more complicated. In most of the cases, MM actually works as an enabler toward novel product and material development (e.g., novel drug molecules in biological application) rather than directly coming up with new products and materials. This precisely is the reason that despite seeing value in MM tools, most engineers and practitioners are often focus on the question, how do I leverage these tools to design and develop novel materials or chemicals for the industry I am working with? Unfortunately, there is no simple answer to this question. Excellent books and very good research publications highlight the most intricate, fundamental, and theoretical details about MM techniques and tools"--Provided by publisher.
  • Molecular pharmacognosy 2013, Springer
    "This book reviews the latest developments in pharmacognosy, introduces a series of new views and insights, presents the hotspots and focus of the field of study on molecular pharmacognosy, and predicts a new direction of study on the resource science of TCM. Furthermore, the book also provides an open communications platform for the development of molecular pharmacognosy."--Publisher.
  • Chemical Hazards in the Organisation / Chris Winder -- Toxicology of Water / Xiaowei Zhang, Steve Wiseman and John Giesy -- Perfluorinated Compounds / Christopher Lau -- Toxicologically Relevant Phthalates in Food / Oliver Kappenstein, Bärbel Vieth, Andreas Luch and Karla Pfaff -- Exposure to Polycyclic Aromatic Hydrocarbons: Bulky DNA Adducts and Cellular Responses / Frank Henkler, Kristin Stolpmann and Andreas Luch -- Heavy Metal Toxicity and the Environment / Paul B. Tchounwou, Clement G. Yedjou, Anita K. Patlolla and Dwayne J. Sutton -- Toxicology of Ambient Particulate Matter / Damiën van Berlo, Maja Hullmann and Roel P. F. Schins -- Nanomaterials: A Challenge for Toxicological Risk Assessment? / Andrea Haase, Jutta Tentschert and Andreas Luch -- Immunotoxicology and Its Application in Risk Assessment /; Andrew A. Rooney, Robert W. Luebke, MaryJane K. Selgrade and Dori R. Germolec.; Chemical Sensitization and Allergotoxicology / Rosette L. Van Den Heuvel, Nathalie Lambrechts, Sandra Verstraelen, Inge C. Nelissen and Greet E. R. Schoeters -- Male Reprotoxicity and Endocrine Disruption / Sarah Campion, Natasha Catlin, Nicholas Heger, Elizabeth V. McDonnell and Sara E. Pacheco, et al. -- Interspecies Uncertainty in Molecular Responses and Toxicity of Mixtures / Moiz M. Mumtaz and Hana R. Pohl -- Recent Trends in Statistical QSAR Modeling of Environmental Chemical Toxicity / Alexander Tropsha -- Chirality and Its Role in Environmental Toxicology / Imran Ali, Hassan Y. Aboul-Enein, Mohd Marsin Sanagi and Wan Aini Wan Ibrahim -- Genetic Variability in Molecular Responses to Chemical Exposure / Chirag J. Patel and Mark R. Cullen -- Biomarkers in Toxicology and Risk Assessment / Bruce A. Fowler -- A Personalized Life: Biomarker Monitoring from Cradle to Grave / Harald Jungnickel and Andreas Luch -- On the Role of Low-Dose Effects and Epigenetics in Toxicology / Lena Smirnova, Alexandra Sittka and Andreas Luch -- Hormesis: Improving Predictions in the Low-Dose Zone / E. J. Calabrese.
  • Morphine and metastasis 2013, Springer
    This book would combine chapters written by the most qualified authors around the world whose research encompasses the effect of morphine or other opioids on tumor growth and metastasis. This includes clinicians involved in trials determining which type of post surgical pain management can minimize the risk of recurrence or metastasis, researchers working on animal models and studying the effect of morphine on tumors, and most importantly the mechanism for this effect, and lastly cell biologists. There is currently a lot of research going on trying to reconcile the pro- and anti-cancer aspects of opioids actions.
  • Muscarinic receptors 2012, Springer
    Muscarinic receptor pharmacology and signaling -- Overview of muscarinic receptor subtypes -- Structure-function studies of muscarinic acetylcholine receptors -- Polymorphisms in human muscarinic receptor subtype genes -- Muscarinic receptor trafficking -- Physiological role of G-protein coupled receptor phosphorylation -- Novel muscarinic receptor mutant mouse models -- Muscarinic receptors in the CNS -- Muscarinic receptor pharmacology and circuitry for the modulation of cognition -- Muscarinic agonists and antagonists in schizophrenia -- Muscarinic pain pharmacology: realizing the promise of novel anagesics by overcoming old challenges -- Muscarinic modulation of striatal function and circuitry -- Muscarinic receptors in brain stem and mesopontine cholinergic arousal functions -- Muscarinic receptors in autonomic effector organs -- Muscarinic receptor agonists and antagonists: effects on ocular function -- Muscarinic receptor agonists and antagonists: effects on cardiovascular function -- Muscarinic receptor antagonists: effects on pulmonary function -- Muscarinic agonists and antagonists: effects on gastrointestinal function -- Muscarinic agonists and antagonists: effets on the urinary bladder -- Muscarinic receptors and mediation of hormonal effects of acetylcholine -- Muscarinic receptor agonists and antagonists: effects on inflammation and immunity -- Muscarinic receptor agonists and antagonists: effects on keratinocyte functions -- Muscarinic receptor agonists and antagonists: effects on cancer -- Activation of muscarinic receptors by non-neuronal acetylcholine.
  • Part 1.Natural Product Drugs and Cancer Therapeutics --The Impact of Natural Products Upon Cancer Chemotherapy /A. Ganesan --Identification and Development of Vascular Disrupting Agents: Natural Products That Interfere with Tumor Growth /Andrea T. Hooper, Frank Loganzo, Chad May and Hans-Peter Gerber --Discodermolide: Past, Present, and Future /Ross E. Longley --HDAC Inhibitors and Other Histone Modifying Natural Products as Emerging Anticancer Agents /Lilibeth A. Salvador and Hendrik Luesch --Natural Product Cytotoxins as Payloads for Antibody Drug Conjugates /Frank E. Koehn --Part 2.Advances in Natural Product Cancer Drug Discovery --Natural Product Scaffolds in Cancer Therapy /Christian P. Mang and Lars Ole Haustedt --The Role of Genetic Engineering in Natural Product-Based Anticancer Drug Discovery /Claudia Eva-Maria Unsin, Scott R. Rajski and Ben Shen --Accessing Anti-cancer Natural Products by Plant Cell Culture /Lisa M. Leone and Susan C. Roberts --Natural Products as Tools for Discovering New Cancer Targets /John A. Beutler.
  • Natural products and drug discovery / Arnold L. Demain and Lixin Zhang -- Integrated approaches for discovering novel drugs from microbial natural products / Lixin Zhang -- Automated analyses of HPLC profiles of microbial extracts: a new tool for drug discovery screening / Jose R. Tormo and Juan B. Garcia -- Manipulating microbial metabolites for drug discovery and production / C. Richard Hutchinson -- Improving drug discovery from microorganisms / Chris M. Farnet and Emmanuel Zazopoulos -- Developments in strain improvement technology: evolutionary engineering of industrial microorganisms through gene, pathway, and genome shuffling / Stephen B. del Cardayr -- The discovery of anticancer drugs from natural sources / David J. Newman and Gordon M. Cragg -- Case studies in natural product optimization: novel antitumor agents derived from Taxus brevifolia and Catharanthus roseus / Jian Hong and Shu-Hui Chen --Terpenoids as therapeutic drugs and pharmaceutical agents / Guangyi Wang, Weiping Tang and Robert R. Bidigare -- Challenges and opportunities in the Chinese herbal drug industry / Wei Jia and Lixin Zhang -- Arsenic trioxide and leukemia: from bedside to bench / Guo-Qiang Chen ... [et al.] -- New methods to access microbial diversity for small molecule discovery / Karsten Zengler, Ashish Paradkar, and Martin Keller -- Accessing the genomes of uncultivated microbes for novel natural products / Asuncion Martinez ... [et al.] -- New natural product diversity from marine actinomycetes / Paul R. Jensen and William Fenical -- Novel natural products from rainforest endophytes / Gary Strobel, Bryn Daisy, and Uvidelio Castillo -- Biological, economic, ecological, and legal aspects of harvesting traditional medicine in Ecuador / Alexandra Guevara-Aguirre and Ximena Chiriboga.
  • This updated edition of Netter's Illustrated Pharmacology allows you to take a distinct visual approach to understanding both the basic science and clinical applications of pharmacology. Designed to be compatible and used in conjunction with other pharmacology resources, this medical reference book offers a vivid, uniquely effective visual presentation of the pharmacodynamic relationship between drugs and the human body. And with the new addition of Student Consult online access, Netter's Illustrated Pharmacology is even more convenient than ever before! Available online for the first time! Search the full contents of Netter's Illustrated Pharmacology no matter what your location with convenient access to Student Consult.Visually grasp the most important principles in pharmacology with succinct, easy-to-understand presentations of introductory pharmacologic principles based on classic images by Frank Netter, as well as dynamic new illustrations from other talented medical artists.Learn how drugs are used to treat specific disorders in the body, as well as their effects on a particular site, with a format divided by organ system and full-color illustrations of the systems themselves.Access in-depth guidance on the must-know elements of each pharmacologic principle with clear, concise notes located beneath the corresponding image.
  • Neurotrophic factors 2014, Springer
    This book provides critical reviews of the role of neurotrophins and their receptors in a wide variety of diseases including neurodegenerative diseases like Huntington's syndrome, cognitive function, psychiatric disorders such as clinical depression, Rett syndrome, motoneurone disease, spinal cord injury, pain, metabolic disease and cardiovascular disease. It also contains contributions from leaders in the field dealing with the basic biology, transcriptional and post-translational regulation of the neurotrophins and their receptors. The present book will review all recent areas of progress in the study of neurotrophins and their biological roles.
  • New drug development -- The regulatory environment -- Drug discovery -- Nonclinical research -- Designing clinical trials -- Conducting clinical trials I: Experimental methodology -- Conducting clinical trials II: Operational execution -- Statistical analysis -- Statistical significance -- Clinical significance -- Sample size estimation -- General safety assessments -- Efficacy assessment -- Cardiac and cardiovascular safety assessments -- Manufacturing small molecule drugs and biologicals -- Postmarketing surveillance -- Main themes and concluding comments -- References -- Index.
  • Global patterns of nicotine and tobacco consumption / S.K. Hammond -- Nicotine chemistry, metabolism, kinetics and biomarkers / N.L. Benowitz, J. Hukkanen and P. Jacob, 3rd -- Nicotine content and delivery across tobacco products / M.V. Djordjevic and K.A. Doran -- The road to discovery of neuronal nicotinic cholinergic receptor subtypes / A.C. Collins ... [et al.] -- Magnetic resonance imaging studies of cigarette smoking / A. Azizian ... [et al.] -- In vivo brain imaging of human exposure to nicotine and tobacco / A. Sharma and A.L. Brody -- Molecular and cellular mechanisms of action of nicotine in the CNS / J. Barik and S. Wonnacott -- The neuronal pathways mediating the behavioral and addictive properties of nicotine / D.J. Balfour -- Molecular genetics of nicotine metabolism / J.C. Mwenifumbo and R.F. Tyndale -- Sex differences in nicotine action / S. Pogun and G. Yararbas -- Recognising nicotine: the neurobiological basis of nicotine discrimination / J.W. Smith and I.P. Stolerman -- Effects of nicotine in experimental animals and humans: an update on addictive properties / B. Le Foll and S.R. Goldberg -- Discriminative stimulus effects of nicotine in humans / K.A. Perkins -- Rodent models of nicotine withdrawal syndrome / D.H. Malin and P. Goyarzu -- Approaches, challenges, and experience in assessing free nicotine / D.L. Ashley ... [et al.] -- Tobacco industry manipulation of nicotine dosing / G.F. Wayne and C.M. Carpenter -- Pharmacotherapy for tobacco dependence / R.V. Fant ... [et al.] -- Nicotine psychopharmacology: policy and regulatory / J.E. Henningfield and M. Zeller.
  • Machine generated contents note: I.Development of Biophar-Maceuticals Defined as Novel Biologics -- 1.Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development / Thomas R. Gelzleichter -- Introduction -- History and Evolution of Biopharmaceuticals -- Development of Diverse Biopharmaceutical Modalities -- Comparison of Small-Molecule Drugs to Biopharmaceuticals -- Summary -- References -- 2.Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological Medicines / Maggie Dempster -- Introduction -- Species Selection -- Study Design Considerations for Repeat-Dose Studies -- Immunogenicity -- Reproductive and Developmental Toxicity -- Genotoxicity and Carcinogenicity -- Special Considerations for Anticancer Drugs -- First-in-Human (Fih) Clinical Trial -- Summary -- References -- 3.Early De-risking Strategy for Novel Biotherapeutics / Beth Hinkle -- Introduction -- Establishing A Safety Profile for Biotherapeutics -- General Safety Considerations Related to Biotherapeutics -- Progress in Evaluation of Immunotoxicity -- Can We Better Address Potential Off-Target Toxicity? -- Summary -- References -- 4.Novel Biopharmaceuticals: Pharmacokinetics, Pharmacodynamics, and Bioanalytics / Wolfgang Seghezzi -- Introduction -- Absorption, Distribution and Elimination of Biopharmaceuticals -- Disposition of Modified Molecules -- "Metabolism" and Biodistribution for Biopharmaceuticals -- Immunogenicity and impacts on PK and biodistribution -- Pharmacokinetics and Pharmacodynamics -- Preclinical to Clinical Translation -- Bioanalytics -- Drug Assays -- Biomarkers: Target Engagement Assays -- Immunogenicity Assessment: ADA Assays -- Summary -- References -- II.Development of Biosimilars -- 5.Overview of Biosimilar Therapeutics / Danuta J. Herzyk -- Introduction -- The Concept of Biosimilars -- General Considerations for Development of Biosimilars -- Biosimilar Candidates Based on Modality and Therapeutic Class -- Summary -- References -- 6.Regulatory Standards for the Approval of Biosimilar Products: A Global Review / Barbara Mounho-Zamora -- Introduction -- European Union -- Pioneer for the First Regulatory Pathway for Biosimilar Products -- The World Health Organization Guidance on Biosimilars -- Regulatory Pathway for Biosimilar Products in the United States -- Biosimilar Pathways in Other Regions -- Summary -- References -- 7.Early Characterization of Biosimilar Therapeutics / Thomas R. Gelzleichter -- Introduction -- Recombinant Insulins -- Recombinant Human Growth Hormone -- Recombinant Erythropoietins -- Recombinant Granulocyte Colony-Stimulating Factor -- Recombinant Interferons -- Low Molecular Weight Heparins -- Monoclonal Antibodies -- Other Classes -- Summary -- References -- III.Vaccines -- 8.Introduction to Vaccines and Adjuvants / Deborah L. Novicki -- Introduction -- The History of Vaccines -- The Impact of Vaccines on Human Health -- Advancements in Vaccines Technologies -- Advancements in Adjuvant Technologies -- Approved Infectious Disease Vaccines and Diseases for Which Preventive Vaccines are Still Needed -- Therapeutic Vaccines -- Product Complexity From a Quality Perspective -- Nonclinical Testing -- Clinical Testing -- Vaccine Development Using the Animal Rule -- The Anti-Vaccines Movement and Misperceptions About Vaccines and Their Safety -- Summary -- References -- 9.Global Regulatory Guidelines for Vaccines / Lisa M. Plitnick -- Introduction -- Toxicity Assessment -- Additional Toxicity Assessments -- Special Considerations -- Formulation/Delivery Devices -- Alternate Routes of Administration -- Special Considerations for Particular Types of Vaccines -- Summary -- References -- 10.Special Considerations for the Nonclinical Safety Assessment of Vaccines / Jayanthi J. Wolf -- Introduction -- De-risking Strategies for Vaccines -- Pharmacokinetics and Pharmacodynamics Assessments -- Differences in the Nonclinical Safety Assessment of Vaccines and Biopharmaceutical Drugs -- Summary -- References -- IV.Specialty Biologics and Indications -- 11.Turning the Corner with Viral-based Gene Therapy -- Development of the Rogue Biopharmaceutical / Timothy K. Maclachlan -- Introduction -- A History and Primer of Gene Therapy -- The Process of Getting Genes into Cells -- Health Authority Regulation of Gene Therapy Products -- Nonclinical Safety Studies and Regulatory Guidance -- Summary -- References -- 12.Blood Products / Vikram Arora -- Introduction -- Plasma-Derived Blood Products -- Blood Products Derived from Recombinant Technologies -- Summary -- References -- 13.Biological Therapies for Cancer / Gautham K. Rao -- Introduction -- Global Regulatory Guidances -- General Principles of Toxicology Assessments -- Nonclinical Studies and Principles of Study Design -- Specialty Toxicology Assessments -- Pharmacokinetics, Immunogenicity, and Pharmacodynamics -- Nonclinical Development of Marketed Biologies -- Recombinant Analogs of Endogeneous Human Proteins (Interferons, Cytokines, Enzymes) -- Summary -- References -- 14.Nonclinical Development of Multi-targeting Biopharmaceuticals / Anu V. Connor -- Introduction -- Scientific Rationale for Multi-Targeting Biopharmaceuticals (MTBs) -- Evolution of Technology Platforms -- General Challenges and Considerations -- Summary of Challenges -- T Cell-Dependent Bispecific Antibody (TDB) Biotherapeutics -- Dual-Targeting Antibodies -- Summary -- References -- 15.Considerations in the Development of Pluripotent Stem Cell-based Therapies / Joy A. Cavagnaro -- Introduction -- Early Decisions -- Nonclinical Development -- Translating Preclinical Data to Clinical Application -- Global Regulatory Guidance -- Summary -- References.
  • A survey of novel molecular targets for anticancer drug discovery -- Microarrays: small spots produce major advances in pharmacogenomics -- Strategies to target chemotherapeutics to tumors -- QSAR and pharmacophore mapping strategies in novel anticancer drug discovery -- Applications of nuclear magnetic resonance and mass spectrometry to anticancer drug discovery -- Antisense strategies for the development of novel cancer therapeutics -- Antibodies and vaccines as novel cancer therapeutics -- Inhibitors as targets for cancer therapy -- Preclinical testing and validation of novel anticancer agents -- Surrogate end points and biomarkers for early trials of novel anticancer agents -- Regulatory considerations in clinical trials of novel anticancer drugs -- Improving the efficacy and safety of anticancer agents: the role of pharmacogenetics -- Imaging of pharmacodynamic end points in clinical trials -- Devising proof-of-concept strategies in oncology clinical trials -- Clinical trial designs for cytostatic agents and agents directed at novel molecular targets -- Cancer gene therapy clinical trials: from the bench to the clinic -- Molecular targets for radiosensitization -- Patient accrual to clinical trials.
  • This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
  • Preface -- Steroid Receptor Coactivators (SRCs) as Integrators of Multiple Signaling Pathways in Cancer Progression -- Role of Alteration/Deficiency in Activation (ADA) Complex in the Cell Cycle, Genomic Instability and Cancer -- RUNX2 Transcriptional Regulation in Development and Disease -- Epigenetic Mechanisms of Cancer Metastasis -- Regulatory Effects of Arsenic on Cellular Signaling Pathways: Biological Effects and Therapeutic Implications -- Nuclear Factors Linking Cancer and Inflammation -- Regulation of the Jak/STATs Pathways by Histone Deacetylases -- Receptor Tyrosine Kinases in the Nucleus: Nuclear Functions and Therapeutic Implications in Cancers -- Nucleolar Signaling Determines Cell Fate The RP-Mdm2-p53 Axis Fine-Tunes Cellular Homeostasis -- Transcriptional Regulation of Lipogenesis as a Therapeutic Target for Cancer Treatment -- Selective Inhibition of Acetyl-Lysine Effector Domains of the Bromodomain Family in Oncology -- Domain Specific Targeting of Cancer -- The Potential of Targeting Splicing for Cancer Therapy -- Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies -- Histone Demethylases in Prostate Cancer -- Therapeutic Significance of Chromatin Remodeling Complexes in Cancer -- Index.
  • 1Antibacterial agents --2Antifungal agents --3Antiviral agents --4Antiparasitic agents --5Antiglaucoma agents --6Neuro-ophthalmology --7Anti-inflammatory agents --8Mydriates, cycloplegics, and reversal agents --9Lubricants and viscoelastics --10Miscellaneous conditions --11Anti-angiogenesis agents --12Contact lens.
  • Oral mucositis 2012, Springer
    Treatment tolerance is a challenge for most cancer patients, and it is therefore essential that healthcare professionals (HCP) are quick to recognize adverse events and implement management strategies to address them. This pocket book provides an in-depth guide to the epidemiology, diagnosis and management of oral mucositis, a common adverse event of chemotherapy.
  • Pasteurella multocida: Diseases and Pathogenesis /I. W. Wilkie, M. Harper, J. D. Boyce and B. Adler --Pathogenomics of Pasteurella multocida /J. D. Boyce, T. Seemann, B. Adler and M. Harper --The Key Surface Components of Pasteurella multocida: Capsule and Lipopolysaccharide /Marina Harper, John D. Boyce and Ben Adler --Pasteurella multocida and Immune Cells /Katharina F. Kubatzky --Molecular Biology of Pasteurella multocida Toxin /Joachim H. C. Orth and Klaus Aktories --Pasteurella multocida Toxin Interaction with Host Cells: Entry and Cellular Effects /Brenda A. Wilson and Mengfei Ho --Swine Atrophic Rhinitis Caused by Pasteurella multocida Toxin and Bordetella Dermonecrotic Toxin /Yasuhiko Horiguchi --The Pasteurella multocida Toxin: A New Paradigm for the Link Between Bacterial Infection and Cancer /Alistair Lax.
  • The Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book-it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science. Contains a collection of experiences of different groups taking different types of biomarkers to different levels of qualification and provides insightful case studies of an important area of regulatory science Focuses on practical advice, concepts, strategies and overall outcomes to support those working toward biomarker qualification for clinical use Offers a valuable resource for members of the regulatory, pharmaceutical and biomarker development communities.
  • Peptide-based drug design 2008, Springer Protocols
    Peptide-based drug design : here and now / Laszlo Otvos, Jr. -- Strategies for the discovery, isolation, and characterization of natural bioactive peptides from the immune system of invertebrates / Philippe Bulet -- Sequence analysis of antimicrobial peptides by tandem mass spectrometry / Christin Stegemann and Ralf Hoffmann -- The spot technique : synthesis and screening of peptide macroarrays on cellulose membranes / Dirk F.H. Winkler and William D. Campbell -- Analysis of A[beta] interactions using ProteinChip technology / Eleni Giannakis ... [et al.] -- NMR in peptide drug development / Jan-Christoph Westermann and David J. Craik -- Molecular dynamics simulations of peptides / Jeffrey Copps, Richard F. Murphy and Sandor Lovas -- Short linear cationic antimicrobial peptides : screening, optimizing, and prediction / Kai Hilpert, Christopher D. Fjell and Artem Cherkasov -- Investigating the mode of action of proline-rich antimicrobial peptides using a genetic approach : a tool to identify new bacterial targets amenable to the design of novel antibiotics / Marco Scocchi ... [et al.] -- Serum stability of peptides / Håvard Jenssen and Stein Ivar Aspmo -- Preparation of glycosylated amino acids suitable for Fmoc solid-phase assembly / Mare Cudic and Gayle D. Burstein -- Synthesis of O-phosphopeptides on solid phase / David Singer and Ralf Hoffmann -- Peptidomimetics : Fmoc solid-phase pseudopeptide synthesis / Predrag Cudic and Maciej Stawikowski -- Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines / Brandon Y. Chua, Weiguang Zeng and David C. Jackson -- Synthesis of a multivalent, multiepitope vaccine construct / Laszlo Otvos, Jr. -- Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins / Marina V. Backer ... [et al.].
  • Translational medicine: a paradigm shift in modern drug discovery and development: the role of biomarkers / Mark Day, J. Lynn Rutkowski, and Giora Z. Feuerstein -- Natural products in drug discovery: present status and perspectives / Gabriella Molinari -- Protein pharmaceuticals: discovery and preclinical development / Davinder S. Gill -- The role of nanobiotechnology in drug discovery / Kewal K. Jain -- Conotoxin venom peptide therapeutics / Richard J. Lewis -- Shark novel antigen receptors: the next generation of biologic therapeutics? / Caroline Barelle, Davinder Gill, and Keith Charlton -- Immune interventions of human diseases through toll-like receptors / Cevayir Coban, Ken J. Ishii, and Shizuo Akira -- Genome-based vaccine development: a short cut for the future / Danilo Gomes Moriel ... [et al.] -- The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections? / Carmen Giefing, Eszter Nagy, and Alexander von Gabain -- HSV as a vector in vaccine development and gene therapy / Peggy Marconi ... [et al.] -- Virus-like particles as a vaccine delivery system: myths and facts / Polly Roy and Rob Noad -- Applications of bacterial ghosts in biomedicine / Petra Lubitz, Ulrike Beate Mayr, and Werner Lubitz -- Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design / Thomas Ebensen and Carlos A. Guzmøn -- Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS / Aurelio Cafaro ... [et al.] -- New strategies to overcome the drawbacks of currently available flu vaccines / Epifanio Fichera ... [et al.].
  • Contains proceedings of the AAPS Stability Workshop.
  • Challenges, opportunities, and evolving landscapes in pharmacogenomics and personalized medicine : an industry perspective / Nadine Cohen and Theresa Frangiosa -- Implementation of pharmacogenomic sample collection in clinical trials / Deborah Sokol Ricci and Monique Franc -- Pharmacogenomics : the regulatory environment and labeling implications / Myong-Jin Kim ... [et al.] -- Applications of pharmacogenomics in drug discovery / Duncan McHale -- Applications of pharmacogenomics in clinical trials / Monique Franc -- Pharmacogenomics applications in drug metabolism : from genotyping to drug label-challenges? / Ann K. Daly -- The genetics of adverse drug reactions : promises and problems / Martin Armstrong -- Strategies and resources for marker selection and genotyping in genetic association studies / Nicole Soranzo, Dong-Jing Fu, and Qingqin S. Li -- Study design and statistical issues in pharmacogenetics research : from candidate genes to genome-wide screens / Nicholas J. Schork, Nathalie Malo, and Eric J. Topol -- Holy SNP, Batman! / Reyna Favis -- Predictive biomarker classifiers in the design of pivotal clinical trials / Richard Simon -- Translation of biomarkers into clinical utility / William L. Trepicchio and George Mulligan -- Pharmacogenomic study feasibility assessment and pharmaceutical business decision-making / Monique Franc and Theresa Frangiosa -- Co-development of drugs and pharmacogenomics-based diagnostics in oncology / Jeffrey S. Ross -- Pharmacogenomics applications in epilepsy / Chantal Depondt -- Pharmacogenomics in Alzheimer's disease / Ramón Cacabelos -- Pharmacogenomics applications in psychiatric disorders / Todd Lencz and Anil K. Malhotra -- Pharmacogenomics in HIV disease / Amalio Telenti -- Pharmacogenomics and cardiovascular drugs / Gérard Siest ... [et al.] -- Pharmacogenomic applications in children / Susan F.A. Grant and Hakon Hakonarson -- Pharmacogenomics of rare and monogenic disorders / Paul D. Maher.
  • Pharmacogenomics principles : introduction to personalized medicine / Parvaz Madadi, and Gideon Koren -- Traditional therapeutic drug monitoring and pharmacogenomics : are they complementary? / Christine Snozek, Loralie J. Langman, and Amitava Dasgupta -- Pharmacogenomics aspect of warfarin therapy / Matthew D. Krasowski -- Pharmacogenetics and cancer chemotherapy / Christine L.H. Snozek -- Pharmacogenomic considerations in anesthesia and pain management / Christine Formea, Wayne T. Nicholson -- Pharmacogenomics of immunosuppressants / Nicolas Picard and Pierre Marquet -- Pharmacogenomics of cardiovascular drugs / Linnea M. Baudhuin -- Pharmacogenomics aspect of antiretroviral therapy / Natella Y. Rakhmanina and John N. van den Anker -- Pharmacogenetics of psychoactive drugs / Jorge L. Sepulveda -- Pharmacogenomic aspects of adverse drug-drug interactions / Loralie J. Langman and Christine Snozek -- Microarray technology and other methods in pharmacogenomics testing / Jorge L. Sepulveda -- Pharmacogenetic testing in the clinical laboratory environment / Mark P. Borgman and Mark W. Linder.
  • Pharmacogenomics methods and protocols 2005, Springer Protocols
  • Ch. 1. Pharmacogenomics principles of alcohol and DOA / Christine L.H. Snozek and Loralie J. Langman -- ch. 2. Alcohol : use and abuse / Amitava Dasgupta -- ch. 3. Slate and trait makers of alcohol abuse / Joshua Bornhorst ... [et al.] -- ch. 4. Introduction to drugs of abuse / Larry Broussard and Catherine Hammett-Stabler -- ch. 5. Pharmacogenomics of amphetamine and related drugs / Steven C. Kazmierczak -- ch. 6. Pharmacogenomics of cocaine / Loralie J. Langman and Christine L.H. Snozek -- ch. 7. Genetic aspect of marijuana metabolism and abuse / Pradip Datta -- ch. 8. Genetic aspect of opiate metabolism and addiction / Jorge L. Sepulveda -- ch. 9. Pharmacogenomics aspects of addiction treatment / F. Gerard Moeller -- ch. 10. Methodologies in pharmacogenetics testing / Jorge L. Sepulveda.
  • ch. 1. Physicochemistry -- ch. 2. Pharmacokinetics -- ch. 3. Absorption -- ch. 4. Distribution -- ch. 5. Clearance -- ch. 6 Renal clearance -- ch. 7. Metabolic (hepatic) clearance -- ch. 8. Toxicity -- ch. 9. Inter-species -- ch. 10. High(er) throughput ADME studies.
  • SECTION I. Basic Principles -- Chapter 1. Basic Principles / Ronald D. Schoenwald -- SECTION II. Industrial and Regulatory Applications -- Chapter 2. PK/PD Approach / Honghui Zhou -- Chapter 3. Pharmacokinetics and Metabolism in Drug Discovery and Preclinical Development / Nishit B. Modi -- Chapter 4. Phase I, II, and III FDA Submissions / Mark G. Eller -- Chapter 5. Bioavailability and Bioequivalence / Veneeta Tandon -- SECTION III. Clinical Applications -- Chapter 6. General Approaches to Clinical Pharmacokinetic Monitoring / Ronald A. Herman -- Chapter 7. Aminoglycosides and Other Antibiotics / Michael E. Klepser and Erika J. Ernst -- Chapter 8. Cardiovascular Agents / John M. Dopp and Bradley G. Phillips -- Chapter 9. Psychotropic Agents / Paul J. Perry -- Chapter 10. Theophylline / Bernd Meibohm -- Chapter 11. Anticonvulsant Agents / Gail D. Anderson -- SECTION IV. Research Applications -- Chapter 12. Classical Modeling / David W A. Bourne -- Chapter 13. Noncompartmental Modeling: An Overview / Ronald A. Herman -- Chapter 14. Physiologically Based Pharmacokinetic Models / James M. Gallo -- Chapter 15. Population Pharmacokinetics / Jeffrey S. Barrett -- Chapter 16. The Linear Systems Approach / Peter Veng-Pedersen -- Index.
  • The natural world with a large number of terrestrial and marine plants and lower organisms is a great source of bioactive compounds historically used as remedies in various diseases. Within the last decade, such compounds became more attractive targets for pharmacologists and the pharmaceutical industry in drug development projects. This volume presents the pharmacological potential of chemically defined natural compounds obtained from plants, fungi, algae and cyanobacteria with antiparasitic activity, that have been tested against various endo-parasitic protozoan and helminth species. --Source other than Library of Congress.
  • Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs.
  • Pharmacology -- Pharmacokinetic Principles -- Introduction to Specialist Therapeutics.
  • Fulltext ClinicalKey
    "Better understand the complexities of pharmacology and physiology relevant to your practice with the brand-new medical reference book, Anesthetic Pharmacology and Physiology. Drs. Hugh Hemmings and Talmage Egan provide the clinical insights you need to effectively administer anesthesia, ensuring patient safety and the most optimal outcomes. Access comprehensive, continually updated research on the physiology of organ systems and clinical topics in the pharmacology of anesthetic drugs. Quickly and easily reference the information you need through user-friendly tables, figures, and algorithms, all presented in lavish full color throughout. Understand the molecular mechanism of drug actions and identify key drug interactions that may complicate anesthesia with dedicated sections on these key areas"--Provided by publisher.
  • Chapter 1. Pharmacology: The Chemical Control of Physiology -- Chapter 2. Drug Affinity and Efficacy -- Chapter 3. Predicting Agonist Effect -- Chapter 4. Drug Antagonism: Orthosteric Drug Effects -- Chapter 5. Allosteric Drug Effects -- Chapter 6. Enzymes as Drug Targets -- Chapter 7. Pharmacokinetics I: Permeation and Metabolism -- Chapter 8. Pharmacokinetics II: Distribution and Multiple Dosing -- Chapter 9. In Vivo Pharmacology -- Chapter 10. Safety Pharmacology -- Chapter 11. Answers to Chapter Questions -- Chapter 12. Derivations and Proofs.
  • "This work is the first monograph devoted solely to Bombax ceiba, popularly known as the Red Silk Cotton Tree. Consisting of seven chapters, it covers all relevant aspects of this plant, from its historical and spiritual importance, to its botanical characterization, pharmacognostical details and ethnobiological uses, to its scientific validation in various animal and human studies. Each part of the tree is of medicinal value and possesses many novel chemical constituents such as shamimicin, bombasin, bombamalone, bombamaloside etc. along with other bioactive secondary metabolites. The book presents the chemical structures of the most important constituents and highlights various pharmacological activities, predominantly antioxidant, anti-inflammatory, anti-mutagenic, hypoglycemic, hypotensive, hepatoprotective and fibrinolytic, which may prove to be a source for the development of a novel phyto-pharmaceutical agent to treat diabetes, heart disease and cancer. In addition, separate chapters deal with the commercial and ecological significance of B. ceiba, as well as a case study on its conservation. Numerous color illustrations are included to identify the plant and to justify its nickname, the “Little Bird's Cafeteria”."--Publisher's website.
  • What is pharmacology? -- How different tissues process drug response -- Drug-receptor theory -- Pharmacological assay formats : binding -- Agonists : the measurement of affinity and efficacy in functional assays -- Orthosteric drug antagonism -- Allosteric drug antagonism -- The process of drug discovery -- Pharmacokinetics -- Target- and system-based strategies for drug discovery -- "Hit" to drug : lead optimization -- Statistics and experimental design -- Selected pharmacological methods -- Exercises in pharmacodynamics and pharmacokinetics.
  • Pharmacology. 4th ed. 2013, ClinicalKey
    Pharmacology, 4th Edition helps you master the "must-know" concepts in this subject and how they apply to everyday clinical problem solving and decision making. This concise yet comprehensive text clearly explains and illustrates challenging concepts and helps you retain the material - from course exams and the USMLE Step 1 right through to clinical practice. Quickly reference essential information thanks to abundant tables throughout, and drug classification boxes at the beginning of each chapter. See how pharmacology applies to practice with real-world case studies. Prepare for exams with self-assessment questions at the end of each chapter. Understand complex concepts visually with the aid of superb full-color illustrations. Access the complete contents online at www.studentconsult.com, along with an additional glossary, chapter-by-chapter summaries and case studies, a full list of featured drugs, 150 USMLE-style questions, animations, and more.
  • Although more than 10 new antiepileptic drugs have been developed in the past decade, epilepsy remains resistant to drug therapy in about one-third of patients, many of whom struggle with the disease their entire lives. Managing these patients is a challenge and requires a structured multidisciplinary approach. The book includes chapters on all issues related to pharmacoresistance in epilepsy, and describes recent developments in the pathogenesis and treatment of this disorder. It addresses abnormalities in inhibitory mechanisms, epilepsy-related changes to the immune system, development of pharmacoresistance caused by chronic exposure to antiepileptic drugs, and novel therapeutic strategies for preventing or slowing down the progression of the disease. Clinicians and basic scientists alike will find up-to-date information on the development of pharmacoresistance, as well as reviews of mechanisms associated with epilepsy that may help them consider novel strategies for preventing the development of pharmacoresistance in the first place. The book also features information on new therapeutic strategies for control of epilepsy, such as transcutaneous electrical stimulation and virtual screening of new antiepileptic drugs. Pharmacoresistance in Epilepsy: From Genes and Molecules to Promising Therapies is useful to anyone working in the field, whether they're studying epilepsy in the lab or treating it in a doctor's office.
  • Definition and classification of pulmonary hypertension / Marc Humbert, David Montani, Oleg V. Evgenov, and Gérald Simonneau -- Pulmonary hypertension: pathophysiology and signaling pathways / Bradley A. Maron and Joseph Loscalzo -- Pulmonary hypertension: pathology / Peter Dorfmüller -- Pulmonary hypertension: biomarkers / Christopher J. Rhodes, John Wharton, and Martin R. Wilkins -- Rodent models of group 1 pulmonary hypertension / John J. Ryan, Glenn Marsboom, and Stephen L. Archer -- General supportive care / Ioana R. Preston -- Calcium-channel blockers in pulmonary arterial hypertension / Marie-Camille Chaumais, Elise Artaud Macari, and Olivier Sitbon -- Prostacyclins / Horst Olschewski -- Endothelin Receptor Antagonists / Martine Clozel, Alessandro Maresta, and Marc Humbert -- Phosphodiesterase-5 inhibitors / Barbara A. Cockrill and Aaron B. Waxman -- Inhaled nitric oxide for the treatment of pulmonary arterial hypertension / Steven H. Abman -- Soluble guanylate cyclase stimulators in pulmonary hypertension / Johannes-Peter Stasch and Oleg V. Evgenov -- Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction / Michael G. Risbano and Mark T. Gladwin -- Rho-kinase inhibitors / Yoshihiro Fukumoto and Hiroaki Shimokawa -- Serotonin transporter and serotonin receptors / Serge Adnot, Amal Houssaini, Shariq Abid, Elisabeth Marcos, and Valérie Amsellem -- Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension / Eva Berghausen, Henrik ten Freyhaus, and Stephan Rosenkranz -- Emerging molecular targets for anti-proliferative strategies in pulmonary arterial hypertension / Ly Tu and Christophe Guignabert -- Anti-inflammatory and immunosuppressive agents in PAH / Jolyane Meloche, Sébastien Renard, Steeve Provencher, and Sébastien Bonnet -- Vasoactive peptides and the pathogenesis of pulmonary hypertension: role and potential therapeutic application / Reshma S. Baliga, Raymond J. MacAllister, and Adrian J. Hobbs -- Pulmonary hypertension: novel pathways and emerging therapies inhibitors of cGMP and cAMP metabolism / Yassine Sassi and Jean-Sébastien Hulot -- Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers) / Geoffrey Watson, Eduardo Oliver, Lan Zhao, and Martin R. Wilkins -- Pulmonary hypertension: current management and future directions / Lewis J. Rubin.
  • v. 2, 2011 Springer
    Vol. 1 / (ix, 306 p.) -- v. 2. / (x, 301 p.).
  • Nutritional genomics / Ruan M. Elliott, James R. Bacon, and Yongping Bao -- Methods to study bioavailability of phytochemicals / Birgit Holst and Gary Williamson -- Characterization of polyphenol metabolites /Andrea J. Day, Joseph A. Rothwell, and Michael R.A. Morgan -- Microarray profiling of gene expression patterns of genistein in tumor cells / Ching Li and Biehuoy Shieh -- Gene regulatory activity of Ginkgo biloba L. / Gerald Rimbach, Rainer Cermak, and Siegfried Wolffram -- Cancer chemoprevention with sulforaphane, a dietary isothiocyanate / Yuesheng Zhang -- Phytochemicals protect against heterocyclic amine-induced DNA adduct formation / Yongping Bao and James R. Bacon -- Organosulfur-garlic compounds and cancer prevention / John Milner -- Polymethylated flavonoids: cancer preventive and therapeutic potentials derived from anti-inflammatory and drug metabolism-modifying properties / Akira Murakami and Hajime Ohigashi -- Biochemical and molecular mechanisms of cancer chemoprevention by tea and tea polyphenols / Jen-Kun Lin -- The role of flavonoids in protection against cataract / Julie Sanderson and W. Russell McLauchlan -- Effects of oltipraz on phase 1 and phase 2 xenobiotic-metabolizing enzymes / Sophie Langouet, Fabrice Morel and Andre Guillouzo -- Future perspectives in phytochemical and health research / Yongping Bao and Roger Fenwick.
  • Absorption and metabolism of anthocyanins and other phenolics in human subjects / Ronald L. Prior -- Absorption and metabolism of the dietary phytochemical, quercetin / Gary Williamson -- Pharmacokinetics and bioavailability of green tea catechins / H-H. Sherry Chow -- The importance of in vivo metabolism of polyphenols and their biological action / Stephen Barnes -- Cancer prevention by phytochemicals, modulation of cell cycle / Diane F. Birt -- Cancer chemoprevention by phytopolyphenols including flavanoids and flavonoids through modulating signal transduction pathways / Jen-Kun Lin -- Gene regulation by glucosinolate hydrolysis products / Elizabeth H. Jeffery -- Healthy food vs. phytosterol fortified foods for primary prevention of coronary artery disease / Douglas S. Lewis -- Vascular effects of resveratrol / Joseph M. Wu -- Development of a mixture of dietary carotenoids as cancer chemopreventive agents: C57BL/6J mice as a useful animal model for efficacy studies with carotenoids / Frederick Khachik -- Chemoprevention of colon cancer by curcumin / Bandaru S. Rdddy.
  • Plant vaccines: an immunological perspective / D.C. Hooper -- Display of peptides on the surface of tobacco mosaic virus particles / M.L. Smith ... [et al.] -- Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality / S. Chebolu and H. Daniell -- Production of antibodies in plants: approaches and perspectives / K. Ko, R. Brodzik and Z. Steplewski -- Plant production of veterinary vaccines and therapeutics / R.W. Hammond and L.G. Nemchinov -- Plant-based oral vaccines: results of human trials / C.O. Tacket.
  • Polymers in drug delivery 2006, CRCnetBASE
  • Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem.
  • Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed "too early" to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest.
  • Progress in drug research v. 62-, 2005-, Springer
  • ch. 1. Molecular Recognition of Nuclear Hormone Receptor-Ligand Complexes / Dr. Robert E. Babine, p. 1-46 -- ch. 2. Kinases / Jerry L. Adams, James Veal and Lisa Shewchuk, p. 47-81 -- ch. 3. The Proteasome as a Drug Target / Tsunehiro Mizushima and Tomitake Tsukihara, p. 83-98 -- ch. 4. Antibiotics and the Ribosome / Jeffrey L. Hansen, p. 99-125 -- ch. 5. Structure-Based Design of Cathepsin K Inhibitors / Daniel F. Veber and Maxwell D. Cummings, p. 127-146 -- ch. 6. Structure-Based Design of Potent and Selective Cdk4 Inhibitors / Teruki Honma, p. 147-170 -- ch. 7. Crystallization and Analysis of Serine Proteases with Ecotin / Sandra M. Waugh and Robert J. Fletterick, p. 171-186 -- ch. 8. X-Ray Crystallography in the Development of Orthogonal Ligand-Receptor Pairs / Donald F. Doyle and Lauren J. Schwimmer, p. 187-207 -- ch. 9. Engineering Proteins to Promote Crystallization / Lei Jin and Robert E. Babine, p. 209-216 -- ch. 10. High-Throughput Crystallography / Harren Jhoti, p. 217-233 -- ch. 11. Micro-Crystallization / Carl L. Hansen, Morten Sommer, Kyle Self, James M. Berger and Stephen R. Quake, p. 235-255.

Shortcut to Licensed Content

Lane Gateway to Licensed Content

Bookmark on other websites

Bookmark on Lane
  • Select "Add to Favorites" (click “Continue” if you see a security alert)
  • From the "Create in" menu, select “Links” (IE7) or “Favorites Bar” (IE8, IE9) to install
  • Once installed it will look like this
  • Click "Bookmark on Lane" to bookmark any webpage
  • Your saved bookmark will appear on this page

Shortcut for iPhone

Lane Gateway to Licensed Content

  • Drag this button to your Safari bookmarks bar
  • Open iTunes and sync your iPhone; make sure "Sync Safari Bookmarks" under iPhone Info tab is selected
  • To invoke the bookmarklet on your iPhone, open Safari and tap the "Bookmarks" icon
  • Tap "Bookmarks Bar"
  • Tap "Lane Proxy Bookmarklet"

What is it?

This shortcut (Lane proxy bookmarklet) gives you access to resources licensed by the library even when you're not coming from a Lane or a Stanford IP address.

While we'd like Lane to be your gateway to our licensed content, we recognize that links to books, articles and journals come from a variety of different sources (Google, your email, RSS reader, etc.).

Lane Proxy Bookmarklet in the Bookmarks Bar

When installed, it will look your browser bookmark.

At the page you would like to proxy, click the "Lane Gateway to Licensed Content" to invoke it.

If Lane licenses that content, you'll get access as if you were on campus.

How does it work?

This shortcut (Lane proxy bookmarklet) is a combination of a browser bookmark and a JavaScript application. In other words, it's a bookmark that can be programmed to do things. The Lane proxy bookmarklet simply prepends the Lane proxy URL to the current URL in your browser.

This allows you to view the URL as though you were on campus, giving you access to materials licensed for use by the Stanford academic community.

If you're not authenticated, you'll be prompted for your SUNetID and password.

Don't see the Toolbar, Bookmarks, or Links or Favorites bar?

FireFox

From the "View" menu, select "Toolbars" & choose "Bookmarks Toolbar"

Safari

From the "View" menu, choose "Show Bookmarks Bar"

Chrome

From the "View" menu, choose "Always Show Bookmarks Bar"

Internet Explorer

IE controller bar
  • Right-click in a clear area near the browser address bar
  • In the menu, check a box next "Links" (IE7) or "Favorites Bar" (IE8, IE9)
  • Managing IE Favorites

Caveats

This shortcut (Lane proxy bookmarklet) only works with resources Lane has licensed and configured to work with our proxy server.

If invoked on a resource we do not license and/or have not yet configured, you will see an error message:

The Lane proxy server cannot complete your request because this host has not been configured properly.

We make no attempt to configure our proxy server for every resource, only those we license and for which a Stanford IP address grants access.

Drag this button onto your browser toolbar to install.

  • Right click this button
  • Select "Add to Favorites", click "Continue" if you see a security alert
  • In "Create in" menu, select "Links" (IE7) or "Favorites Bar" (IE8, IE9) to install

Drag this button onto Safari Bookmarks bar to install.

Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities. In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities. In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.Large number of high quality software and database programming titles from O'Reilly. Other software titles are also available from Sams and Prentice Hall. Limited to 7 concurrent users.Vast collection of software and database programming titles from multiple publishers, including Microsoft Press.Largest provider of engineering-related eBooks; includes titles in computer science and biomedical engineering.Over 4,000 full-text e-books covering scientific and technical information from CRC Press and others. Many handbooks and single volume reference sources.A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more. Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.Includes peer-reviewed life science and biomedical research protocols compiled from Methods in Molecular Biology, Methods in Molecular Medicine, Methods in Biotechnology, Methods in Pharmacology and Toxicology, Neuromethods, the Biomethods Handbook, the Proteomics Handbook, and Springer Laboratory Manuals.Contains full text access to selected biomedical and nursing books.Provides one-click access to important clinical resources; includes evidence-based diagnosis and treatment guidelines, Books, EBM articles, Ovid MEDLINE, Drug facts and comparisons, Drug interaction facts, guidelines from National Guideline Clearinghouse, patient handouts (English and Spanish), and local content.MD consult provides access to textbooks, electronic journals, practice guidelines, drug information, and patient education handouts.A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.Provides online, full-text access to Springer's journal titles as well as journals from other publishers. Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.
FEEDBACK